Disclosures SG has been a consultant and is an investigator in Novartis-sponsored studies, he owns no stock or option; DA has received honoraria and research support from Novartis, Pfizer, Janssen-Cilag, H. Lundbeck, AstraZeneca, he owns no stock or option; JBL has been a consultant for GlaxoSmithKline, and consultant and speaker for Novartis Pharmaceuticals; DW has served as a consultant to Novartis.
Diagnosis and management of Parkinson’s disease dementia
Article first published online: 8 SEP 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 62, Issue 10, pages 1581–1587, October 2008
How to Cite
Poewe, W., Gauthier, S., Aarsland, D., Leverenz, J. B., Barone, P., Weintraub, D., Tolosa, E. and Dubois, B. (2008), Diagnosis and management of Parkinson’s disease dementia. International Journal of Clinical Practice, 62: 1581–1587. doi: 10.1111/j.1742-1241.2008.01869.x
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
- Issue published online: 8 SEP 2008
- Article first published online: 8 SEP 2008
- Paper received May 2008, accepted July 2008
Parkinson’s disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer’s disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.